Summary:
A Phase I, Single-dose, Parallel Group Study to Assess the Pharmacokinetics of Olorofim in Subjects with Hepatic Impairment
Qualified Participants Must:
Be 18 to 70 Years Old
Have a BMI between 18 and 35
Have been diagnosed with liver issues or liver disease